Microbix & BioGX Collaborate on real-time PCR Assays & Controls

By Microbix Admin | December 7, 2023

Microbix Announces Initiation of Normal Course Issuer Bid

By Microbix Admin | December 6, 2023

Microbix Presenting at Florida Capital Event Conference

By Microbix Admin | November 17, 2023

Microbix Clot-Buster Drug Fully-Funded For Return to U.S. Market

By Microbix Admin | November 16, 2023

Microbix & Ulisse Biomed Collaborate on HPV Controls & Assays

By Microbix Admin | November 10, 2023

Microbix QAPs Supporting HPV Testing in Ireland

By Microbix Admin | October 27, 2023

Episode 3: Diagnostics: Beyond the lab – Self-Collection with Copan Italia

By Microbix Admin | October 21, 2023

Episode 5: Diagnostics Beyond the Lab: Bridging Policy and innovation for a healthier tomorrow

By Microbix Admin | October 20, 2023

Microbix Presenting at Muskoka Capital Conference

By Microbix Admin | September 29, 2023

Microbix Achieves New QAPs Sales Record

By Microbix Admin | September 27, 2023

Microbix Honours the Passing of its Founder William J. Gastle – 1948 to 2023

By Microbix Admin | September 13, 2023

Microbix Reports Results for Q3 Fiscal 2023

By Microbix Admin | August 10, 2023

Microbix Successfully Upgrades Logistics Software Systems

By Microbix Admin | August 7, 2023

Microbix Presents Results of STI Test Controls at AACC

By Microbix Admin | July 24, 2023

Microbix QAPs Supporting HPV Testing Across The Netherlands

By Microbix Admin | July 5, 2023

Respiratory virus multiplex formulations desiccated on Copan’s FLOQSwab© for use as cross-platform compatible EQA samples – and laboratory Quality Control

By Microbix Admin | June 20, 2023

Microbix & Labquality Create Novel Testing Accreditation Program

By Microbix Admin | June 20, 2023

Evaluating the performance of STI POC assays using Swab format Quality Controls

By Microbix Admin | June 18, 2023

Performance of NAAT that detect MGEN using Swab Quality Controls

By Microbix Admin | June 18, 2023

Microbix Secures Funded Drug Commercialization Agreement

By Microbix Admin | May 16, 2023

Microbix Reports Results for Q2 Fiscal 2023

By Microbix Admin | May 11, 2023

Episode 4: Diagnostics Beyond the Lab: Ensuring Patient Health through EQA

By Microbix Admin | April 24, 2023

Diagnostics Explained: AMR

By Microbix Admin | February 21, 2023

CEM Muskoka – September 23-25

By Microbix Admin | February 8, 2023

Upcoming Events 2023

By Microbix Admin | February 2, 2023

Upcoming Events: Coming Soon

By Microbix Admin | January 27, 2023

Blog: Episode 3

By Microbix Admin | January 13, 2023

Blog: Episode 2

By Microbix Admin | January 10, 2023

Blog: Episode 1

By Microbix Admin | January 5, 2023

2022 Q2 Financial Report

By Microbix Admin | November 11, 2022

High-Risk HPV Quality Controls are Needed to Uphold Clinical Laboratory Quality Standards

By Microbix Admin | November 10, 2022

Emerging requirements for infectious disease IVD quality control material

By Microbix Admin | November 10, 2022

Expected stability of REDx&#8482FLOQ © SARS-CoV-2 Swab Positive Control and REDx&#8482FLOQ© SARS-CoV-2 Swab Negative Control in various sample transport media and storage conditions

By Microbix Admin | November 9, 2022

2022 Q3 Financial Report

By Microbix Admin | November 9, 2022

Use of REDx™FLOQ © SARS-CoV-2 Ag Swab Positive Control and REDx™FLOQ© Respiratory Swab Negative Control as Quality Control by POC devices in various testing conditions

By Microbix Admin | November 8, 2022

Novel Cross-Platform High-Risk (hr) HPV NAAT Positive Controls for Use in L1 and E6/E7 Targeted Nucleic ACID (DNA and RNA) Detection Methods

By Microbix Admin | November 8, 2022

Cross-Platform High-Risk (hr) Low Occurrence HPV NAAT Positive Samples of Use in Nucleic Acid Detection Testing as Prospective External Quality Assessment Samples – and User Defined Quality Controls

By Microbix Admin | November 8, 2022

Performance of full and extended genotyping assays using a new high-risk HPV multiplex panel

By Microbix Admin | November 7, 2022

Respiratory virus multiplex formulations desiccated on Copan’s FLOQSwab® for use as cross-platform compatible EQA samples and laboratory Quality Control

By Microbix Admin | November 6, 2022

Novel Mycoplasma genitalium (Mgen) and AMR Mgen A2059G Materials for use in a Cross-Platform NAAT Quality Control

By Microbix Admin | November 6, 2022

Simulated swab specimens for whole workflow quality control of SARS-CoV-2 molecular diagnostic testing

By Microbix Admin | November 5, 2022

2022 Q1 Financial Report

By Microbix Admin | November 5, 2022

Advanced SARS-CoV-2 Variants of Concern (VOC) whole-genome materials for use as verification, external quality assessment (EQA) and prospective quality control samples

By Microbix Admin | November 4, 2022

Episode 2: Diagnostics: Beyond the Lab – AMR MGEN with Colin Denver from SpeeDx

By Microbix Admin | November 4, 2022

Advanced SARS-CoV-2 nucleocapsid protein swab-based formulation for use as a cross-platform EQA sample and as a prospective Quality Control

By Microbix Admin | November 3, 2022

Novel neutralizing anti-S1 SARS-CoV-2 human monoclonal antibody formulation for use as a cross-platform EQA sample and prospective quality controls

By Microbix Admin | November 2, 2022

Novel SARS-CoV-2 Full-Genome Material for Use in a Swab-Based Formulation as a Multi-Platform NAAT Quality Control

By Microbix Admin | November 1, 2022

Episode 1: Diagnostics: Beyond the lab – HPV with Larry Vaughn, BD and Dr. Cathy Popadiuk

By Microbix Admin | November 1, 2022

MBX Investor Update Webinar